Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

HUTCHMED Receives ELUNATE Marketing Approval In Hong Kong For Treatment Of Metastatic Colorectal Cancer

Author: Benzinga Newsdesk | January 30, 2024 03:20am
  • First medicine approved under new "1+" mechanism by HKSAR Government, providing an important treatment option to patients in Hong Kong —
  • ELUNATE® is the first oral targeted therapy approved in Hong Kong for metastatic colorectal cancer regardless of biomarker status or prior types of therapies in almost a decade —
  • Fruquintinib already approved in mainland China, Macau SAR and the United States —

Posted In: HCM


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist